Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has been given a consensus rating of “Hold” by the eleven research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $51.50.
A number of research firms have weighed in on RHHBY. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective for the company in a research note on Friday, April 24th. Zacks Research downgraded shares of Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, HSBC cut shares of Roche from a “buy” rating to a “hold” rating in a report on Monday, July 6th.
View Our Latest Stock Report on RHHBY
Institutional Trading of Roche
Roche Price Performance
Shares of OTCMKTS RHHBY opened at $56.41 on Thursday. Roche has a 1 year low of $37.51 and a 1 year high of $60.85. The firm has a 50-day moving average of $51.95 and a 200 day moving average of $52.84. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12.
Roche Company Profile
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).
In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.
Further Reading
- Five stocks we like better than Roche
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
